IL6 and breast carcinoma: Based on receiver operating characteristic (ROC) curve analysis, interleukin-6 (IL-6) was found to exhibit significant diagnostic performance for breast cancer (0.825, 95% confidence interval: 0.549–0.94, P = 0.030) (Zare Moayedi et al., 2021).